The WSAVA Therapeutic Guidelines Group (TGG) is looking for partners to sponsor a wide range of activities that are expected to have a tremendous impact on the global veterinary community over the years to come. The mission of the TGG is to ensure best practices for the selection and use of medicines including their quality, availability and responsible use in companion animals while engaging participation of stakeholders and the WSAVA Global Community under the concept of One Health. The pharmaceutical industry is a key stakeholder for us since our activities have clear implications for manufacturing, distribution and use of veterinary medicines. In 2019, our work has mainly focused on the development of a list of essential medicines for companion animals. The document has been open for public consultation and the final version is going to be launched in the beginning of 2020. We have also generated a set of recommendations to guide users in assessing ethical and safety implications for counterfeit medicines and products purchased from online pharmacies. The latter activity should benefit our stakeholders and indirectly protect the interests of the pharmaceutical industry. A number of activities are in the TGG production pipeline for the years to come. Here are some examples of what we have planned to do:

- Launch an awareness campaign on the issue of drug unavailability and quality of medicines aligned with the list of essential medicines for companion animals (a panel discussion is planned for the WSAVA/FECAVA congress in Poland in 2020).
- Perform a pilot study to assess the quality of selected essential medicinal products on a global scale using amoxicillin clavulanate as a model drug.
- Produce an online course on responsible antimicrobial use targeting veterinary small animal practitioners in collaboration with HealthforAnimals.
- Publish a review on the definition of responsible/rational antimicrobial use, highlighting pre- and post-treatment activities that are essential for implementing best antimicrobial practices in small animal medicine.
- Summarize all the available guidelines pertaining to antimicrobial use in companion animals and make them publicly available on the TGG homepage.
- Develop practical summaries with flow charts, fact sheets and infographics of the ISCAID guidelines for superficial pyoderma, respiratory and urinary tract infections, and translate them into a wide range of languages in collaboration with WSAVA Translation Committee.
• Publish a position paper addressing the methodology for developing and implementing evidence-based antimicrobial use guidelines, the importance of regional and national guidelines, priority topics for future guidelines, and research needs to improve the quality of evidence.
• Complete a survey to outline antimicrobial use practices and access to guidelines among WSAVA members.
• Establish a global network to collect data at the regional level, contribute to OIE global data collection on antimicrobial agents intended for use in companion animals, identify short term/acute shortages and barriers to drug access or proper drug use, and resolve them using a collaborative approach with the relevant stakeholders including the governmental authorities.

We are a very motivated interdisciplinary group with several renowned experts who are ready to make a difference in the veterinary profession. Potential sponsors are welcome to suggest additional activities that are in line with our vision and strategy, which are available on the TGG homepage together with the biographies of our group members (https://www.wsava.org/Committees/Therapeutics-Guidelines-Group).

If you are interested in learning more about the TGG or sponsoring any of the individual projects outlined above, please contact the WSAVA CEO, Arpita Bhose at yourwsava@wsava.org

We look forward to hearing from you.

Best wishes,
Luca Guardabassi and Paulo Steagall
Co-chairs, WSAVA Therapeutic Guidelines Group